The Efficacy and Safety of Bevacizumab Plus Anti-PD-1/PD-L1 Inhibitors in Combination with Hepatic Arterial Infusion Chemotherapy for Initially Unresectable Hepatocellular Carcinoma
Triple combination therapy demonstrated significant therapeutic efficacy and tumor response in initially uHCC. No notable differences in outcomes were observed between the BP1-HAIC and BPL-HAIC groups. AEs were manageable in clinical practice.
Authors
- Dandan Hu (ORCID: https://orcid.org/0000-0001-7905-8536)
- Yizhen Fu (ORCID: https://orcid.org/0000-0003-1919-7176)
- Yaojun Zhang (ORCID: https://orcid.org/0000-0002-9752-4729)
- Xiang Tang (ORCID: https://orcid.org/0000-0003-2332-5353)
- Wei Peng (ORCID: https://orcid.org/0000-0002-5780-2157)
- Zhongguo Zhou (ORCID: https://orcid.org/0000-0002-1929-4278)
- Jinbin Chen (ORCID: https://orcid.org/0000-0002-6619-1247)
- Hu Li (ORCID: https://orcid.org/0000-0002-7917-7807)
- Juncheng Wang (ORCID: https://orcid.org/0000-0003-0539-0063)
- Minshan Chen (ORCID: https://orcid.org/0000-0002-6116-5015)
- Zhoutian Yang (ORCID: https://orcid.org/0009-0008-7704-3494)
- Zhiwei Ye (ORCID: https://orcid.org/0000-0003-4180-9239)
Institutions
- Sun Yat-sen University (CN)
- Sun Yat-sen University Cancer Center (CN)
Publication Details
- Journal
- ImmunoTargets and Therapy
- Published
- 2024-10-01
- DOI
- https://doi.org/10.2147/itt.s478685
- Citations
- 3
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.11
Funders
- National Natural Science Foundation of China
- Basic and Applied Basic Research Foundation of Guangdong Province